Greedy Gilead – AHF


Press:

AHF Labels Gilead ‘War Profiteer’ and ‘Greedy Bastards!’ as Company Prices COVID Drug at $2K to $3K

In Featured, Gilead, News by Ged KensleaJune 30, 2020

In May, AIDS Healthcare Foundation demanded that the drug company price remdesivir, the newly approved drug for treating COVID-19—which Gilead had developed years earlier with $70M in government funding as …

Read More

AHF Demands Gilead Price Remdesivir at $1.00 per Dose

In Featured, Gilead, News by Ged KensleaMay 12, 2020

WASHINGTON (May 12, 2020) AIDS Healthcare Foundation (AHF) today demanded that remdesivir, the newly approved drug for treating COVID-19, be priced at no more than one U.S. dollar per dose. …

Read More

AHF Welcomes U.S. Reps. Doggett and DeLauro’s Inquiry re: Gilead’s Use of Public Funds Developing COVID-19 Treatment

In Featured, Gilead, News by Ged KensleaMay 4, 2020

WASHINGTON (May 4, 2020) AIDS Healthcare Foundation (AHF) today praised the work of U.S. Representatives Lloyd Doggett (D-TX) and Rosa DeLauro (D-CT) for their demand for an accounting of how …

Read More

AHF Signs On to Open Letter to Gilead Urging Access to Remdesivir as COVID-19 Treatment

In Featured, Gilead, News by Ged KensleaMarch 30, 2020

Mr Daniel O’Day Chief Executive Officer Gilead Science, Inc. Dear Mr O’Day, Open letter to Gilead concerning ensuring access to remdesivir We write to request that Gilead take immediate actions …

Read More

AHF Demands Gilead Drop Exclusive ‘Orphan Drug’ Claim on COVID-19 Treatment

In Featured, Gilead, News by Ged KensleaMarch 25, 2020

In an unconscionable move amidst the unfolding global pandemic, Gilead Sciences, Inc. is using publicly funded research for an exclusive ‘orphan drug’ monopoly designation on a possible COVID-19 treatment …

Read More

Want to read more on the subject?

See More articles